In women who are menstruating regularly, but with anovular cycles, the initial course of treatment consists of 20 mg given daily on the second, third, fourth and fifth days of the menstrual cycle. Elderly people: Similar dosing regimens of tamoxifen have been used in older people with breast cancer and in some of these patients it has been used as sole therapy. Anovulatory infertility: Before commencing any course of treatment, whether initial or subsequent, the possibility of pregnancy must be excluded. Substantive evidence supporting the use of treatment with 30-40mg per day is not available, although these doses have been used in some patients with advanced disease. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. The primary prevention of breast cancer in women at moderate or high risk (see section 5.1) Women aged less than 30 years old were excluded from primary prevention trials so the efficacy and safety of tamoxifen treatment in these younger women is unknown. Breast cancer: Adults: The recommended daily dose of tamoxifen is normally 20mg. If unsatisfactory basal temperature records or poor pre-ovulatory cervical mucus indicate that this initial course of treatment has been unsuccessful, further courses may be given during subsequent menstrual periods, increasing the dosage to 40mg and then 80mg daily. In women who are not menstruating regularly, the initial course may begin on any day. A study has found that the antidepressant Effexor (chemical name: venlafaxine) eased hot flashes just as well as hormone replacement therapy (HRT). There are two types of antidepressant medicines: SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin and norepinephrine reuptake inhibitors). The research was published online on May 26, 2014 by . Read the abstract of “Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms: A Randomized Clinical Trial.” Menopausal symptoms such as hot flashes and night sweats can dramatically reduce quality of life for some women. Hot flashes also are a known side effect of hormonal therapy medicines used to treat breast cancer. Doctors call hot flashes and night sweats “vasomotor symptoms.” Some women use hormone replacement therapy (HRT) to ease these symptoms. But research has shown that HRT increases breast cancer risk in women who haven’t been diagnosed. HRT also increases the risk of breast cancer coming back (recurrence) in women who have been diagnosed with the disease.
Tamoxifen is a hormone therapy drug taken by many premenopausal women after completing their initial treatments for estrogen receptor positive breast cancer. To treat the side effects of tamoxifen such as hot flashes and to help with depression, doctors often prescribe antidepressants. Wellbutrin XL by GSK 150 mg, 30 extended-release tablets. Manufactured in Germany Original price $ 45.00